VIVSHealthcare · Biotechnology

VIVS Stock Forecast: VivoSim Labs, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026

$0.15

+8.71% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 4 Nov 2026 — in the lower half.

Market cap

$2.3M

Ticker Nerd rank

36/ 100

Median analyst target

—

Analysts covering

—

Revenue$18K−51.4% y/y

Operating income−$2.8M

Net income−$1.3M

Free cash flow−$3.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+1.5%

−23.9%

YTD

−91.6%

−93.1%

From 52W high

−94.8%

From 52W low

+8.7%

$0.14

$2.92

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

VIVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VivoSim Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026

36/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Issuance

Volatility

Growth

Quality

Revisions

Momentum

Value

Size (97): Smaller than most of the companies we track.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VIVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VIVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VIVS appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

VIVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, VivoSim Labs, Inc. returned −93.1% against +14.8% for the S&P 500, dividends included.

VIVS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VIVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

VivoSim Labs, Inc. (VIVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.5×
Price / sales: 22.7×
Price / book: −0.2×
EV / EBITDA: −0.1×

Growth & margins

Revenue growth (YoY): −51.4%
Earnings growth (YoY): −51.4%
Gross margin: 100.0%
Operating margin: −15327.8%
Net margin: 100.0%

Returns & dividend

Return on equity: −343.1%
Return on assets: −89.5%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

VivoSim Labs, Inc. (VIVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

VivoSim Labs, Inc. has a market value of $2.3M and an enterprise value of $779K.
Revenue in the twelve months to 30 June 2026: $112K. The latest quarter shrank 51.4% year on year.
Net income over the same four quarters: −$12.3M, a −11016.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$10.1M.
Shares outstanding: 3.2M.
Trailing P/E: 0.5×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
VivoSim Labs, Inc. employs 15 people — $7K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

VIVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VIVSVivoSim Labs, Inc.	$2.3M	36
APVOAptevo Therapeutics, Inc.	$2.5M	27
HCWBHCW Biologics Inc.	$2.4M	54
CLDICalidi Biotherapeutics, Inc.	$2.7M	23
NRSNNeurosense Therapeutics Ltd.	$2.7M	3
DCOYDecoy Therapeutics, Inc.	$2.7M	19
REVBRevelation Biosciences, Inc.	$2.3M	11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VivoSim Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VIVS news & analysis

VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test

GlobeNewsWire · 3 Nov 2026positive

VivoSim Labs and Chemveda Life Sciences announced a collaboration pairing Chemveda’s molecule design and production with VivoSim’s NAMkind 3D human liver and intestine models to assess drug candidates for safety. The companies say the process can identify candidates to advance in weeks rather than years.

Why it matters — VIVS watchers may note the collaboration as an application of VivoSim’s human models in evaluating AI-designed drug candidates.

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

GlobeNewsWire · 21 Oct 2026positive

VivoSim Labs said it has extended its NAMkind platform with patient-derived liver and intestinal disease models for efficacy testing and mechanistic biomarker profiling. The models are designed to help drug developers assess whether a candidate reduces human disease in tissue before clinical trials.

Why it matters — The extension adds disease-model testing capabilities to VIVS’s platform for drug developers.

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

GlobeNewsWire · 7 Oct 2026positive

VivoSim Labs highlighted updated FDA regulations allowing greater use of non-animal testing methods, saying its human-relevant models are already helping lower drug costs.

Why it matters — The regulatory change and the company's stated use of human-relevant models are relevant to VIVS watchers tracking its role in non-animal safety testing.

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

GlobeNewsWire · 16 Sept 2026positive

VivoSim Labs presented new NAMkind™ drug toxicity data at EUROTOX 2026 in Vienna, highlighting long-term repeat-dose modeling, mechanistic GI barrier profiling, and the deconvolution of payload- and linker-dependent toxicities. The data reportedly demonstrates predictive superiority in liver and gastrointestinal safety across small molecules and antibody-drug conjugates.

Why it matters — The presentation signals advanced predictive capabilities in drug safety assessment, which could strengthen VIVS's position in the toxicity-modeling market.

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

GlobeNewsWire · 1 Sept 2026positive

VivoSim Labs announced it is adding a rat liver model to its NAMkind platform, a new cross-species capability designed to help pharmaceutical companies distinguish rat-specific liver toxicity from risks that may translate to humans.

Why it matters — This expands the platform's offerings to help drug developers better assess liver toxicity risk across species, potentially strengthening VivoSim's value proposition in preclinical safety testing.

FAQ

Frequently asked questions about VIVS stock

How does Ticker Nerd's model rank VIVS?

As at 4 Nov 2026, VivoSim Labs, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the VIVS stock forecast for 2030?

No analyst covering VivoSim Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIVS are extrapolating price history, which says nothing about the business.

How has VIVS stock performed over the past year?

VivoSim Labs, Inc. returned -93.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VivoSim Labs, Inc. do?

VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine.

What is the latest news on VIVS?

The most recent item we track (GlobeNewsWire, 3 Nov 2026): "VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test". VivoSim Labs and Chemveda Life Sciences announced a collaboration pairing Chemveda’s molecule design and production with VivoSim’s NAMkind 3D human liver and intestine models to assess drug candidates for safety. The companies say the process can identify candidates to advance in weeks rather than years.

Company

About VivoSim Labs, Inc.

VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The company provides human-relevant toxicology insights through its new approach methodologies, including customizable NAMkind™ models designed to evaluate liver toxicity, intestinal toxicity, permeability, and related drug properties. VivoSim Labs also supports investigational toxicology, mechanism-of-action studies, predictive screening, and research services for pharmaceutical and biotechnology partners at different stages of drug development. Based in San Diego, California, VivoSim Labs plays a specialized role in preclinical testing by using complex human tissue systems to help researchers study drug behavior in a more biologically relevant environment.

15 employees · United States · https://vivosim.ai